目次

Table of Contents

Chapter 1. Methodology and Scope
1.1. Market Segmentation and Scope
1.2. Market Definitions
1.3. Research Methodology
1.3.1. Information Procurement
1.3.2. Information or Data Analysis
1.3.3. Market Formulation & Data Visualization
1.3.4. Data Validation & Publishing
1.4. Research Scope and Assumptions
1.4.1. List of Data Sources

Chapter 2. Executive Summary
2.1. Market Outlook
2.2. Segment Outlook
2.3. Competitive Insights

Chapter 3. Amyloidosis Treatment Market Variables, Trends, & Scope
3.1. Market Introduction/Lineage Outlook
3.2. Market Size and Growth Prospects (USD Million)
3.3. Market Dynamics
3.3.1. Market Drivers Analysis
3.3.2. Market Restraints Analysis
3.4. Amyloidosis Treatment Market Analysis Tools
3.4.1. Porter’s Analysis
3.4.1.1. Bargaining power of the suppliers
3.4.1.2. Bargaining power of the buyers
3.4.1.3. Threats of substitution
3.4.1.4. Threats from new entrants
3.4.1.5. Competitive rivalry
3.4.2. PESTEL Analysis
3.4.2.1. Political landscape
3.4.2.2. Economic and Social landscape
3.4.2.3. Technological landscape
3.4.2.4. Environmental landscape
3.4.2.5. Legal landscape

Chapter 4. Amyloidosis Treatment Market: Treatment Estimates & Trend Analysis
4.1. Segment Dashboard
4.2. Amyloidosis Treatment Market: Treatment Movement Analysis, 2023 & 2030 (USD Million)
4.3. Chemotherapy
4.3.1. Chemotherapy Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
4.4. Immunosuppressive Drugs
4.4.1. Immunosuppressive Drugs Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
4.5. Transplantation
4.5.1. Transplantation Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
4.6. Supportive Care
4.6.1. Supportive Care Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
4.7. Surgery
4.7.1. Surgery Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
4.8.1. Others Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 5. Amyloidosis Treatment Market: End Use Estimates & Trend Analysis
5.1. Segment Dashboard
5.2. Amyloidosis Treatment Market: End Use Movement Analysis, 2023 & 2030 (USD Million)
5.3. Hospitals and Clinics
5.3.1. Hospitals and Clinics Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
5.4. Ambulatory Surgical Centers
5.4.1. Ambulatory Surgical Centers Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
5.5. Home Care Settings
5.5.1. Home Care Settings Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
5.6. Others
5.6.1. Others Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 6. Amyloidosis Treatment Market: Regional Estimates & Trend Analysis
6.1. Amyloidosis Treatment Market Share, By Region, 2023 & 2030, USD Million
6.2. North America
6.2.1. North America Amyloidosis Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million)
6.2.2. U.S.
6.2.2.1. U.S. Amyloidosis Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million)
6.2.3. Canada
6.2.3.1. Canada Amyloidosis Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million)
6.2.4. Mexico
6.2.4.1. Mexico Amyloidosis Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million)
6.3. Europe
6.3.1. Europe Amyloidosis Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million)
6.3.2. UK
6.3.2.1. UK Amyloidosis Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million)
6.3.3. Germany
6.3.3.1. Germany Amyloidosis Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million)
6.3.4. France
6.3.4.1. France Amyloidosis Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million)
6.3.5. Italy
6.3.5.1. Italy Amyloidosis Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million)
6.3.6. Spain
6.3.6.1. Spain Amyloidosis Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million)
6.3.7. Denmark
6.3.7.1. Denmark Amyloidosis Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million)
6.3.8. Sweden
6.3.8.1. Sweden Amyloidosis Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million)
6.3.9. Norway
6.3.9.1. Norway Amyloidosis Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million)
6.4. Asia Pacific
6.4.1. Asia Pacific Amyloidosis Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million)
6.4.2. Japan
6.4.2.1. Japan Amyloidosis Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million)
6.4.3. China
6.4.3.1. China Amyloidosis Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million)
6.4.4. India
6.4.4.1. India Amyloidosis Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million)
6.4.5. Australia
6.4.5.1. Australia Amyloidosis Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million)
6.4.6. South Korea
6.4.6.1. South Korea Amyloidosis Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million)
6.4.7. Thailand
6.4.7.1. Thailand Amyloidosis Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million)
6.5. Latin America
6.5.1. Latin America Amyloidosis Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million)
6.5.2. Brazil
6.5.2.1. Brazil Amyloidosis Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million)
6.5.3. Argentina
6.5.3.1. Argentina Amyloidosis Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million)
6.6. Middle East and Africa
6.6.1. Middle East and Africa Amyloidosis Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million)
6.6.2. South Africa
6.6.2.1. South Africa Amyloidosis Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million)
6.6.3. Saudi Arabia
6.6.3.1. Saudi Arabia Amyloidosis Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million)
6.6.4. UAE
6.6.5. UAE Amyloidosis Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million)
6.6.6. Kuwait
6.6.6.1. Kuwait Amyloidosis Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 7. Competitive Landscape
7.1. Recent Developments & Impact Analysis by Key Market Participants
7.2. Company Categorization
7.3. Company Heat Map Analysis
7.4. Company Profiles
7.4.1. Pfizer Inc.
7.4.1.1. Participant’s Overview
7.4.1.2. Financial Performance
7.4.1.3. Product Benchmarking
7.4.1.4. Recent Developments/ Strategic Initiatives
7.4.2. Johnson & Johnson Services, Inc.
7.4.2.1. Participant’s Overview
7.4.2.2. Financial Performance
7.4.2.3. Product Benchmarking
7.4.2.4. Recent Developments/ Strategic Initiatives
7.4.3. GSK plc
7.4.3.1. Participant’s Overview
7.4.3.2. Financial Performance
7.4.3.3. Product Benchmarking
7.4.3.4. Recent Developments/ Strategic Initiatives
7.4.4. Takeda Pharmaceutical Company Limited
7.4.4.1. Participant’s Overview
7.4.4.2. Financial Performance
7.4.4.3. Product Benchmarking
7.4.4.4. Recent Developments/ Strategic Initiatives
7.4.5. Amgen Inc.
7.4.5.1. Participant’s Overview
7.4.5.2. Financial Performance
7.4.5.3. Product Benchmarking
7.4.5.4. Recent Developments/ Strategic Initiatives
7.4.6. Bristol-Myers Squibb Company
7.4.6.1. Participant’s Overview
7.4.6.2. Financial Performance
7.4.6.3. Product Benchmarking
7.4.6.4. Recent Developments/ Strategic Initiatives
7.4.7. Novartis AG
7.4.7.1. Participant’s Overview
7.4.7.2. Financial Performance
7.4.7.3. Product Benchmarking
7.4.7.4. Recent Developments/ Strategic Initiatives
7.4.8. F. Hoffmann-La Roche Ltd
7.4.8.1. Participant’s Overview
7.4.8.2. Financial Performance
7.4.8.3. Product Benchmarking
7.4.8.4. Recent Developments/ Strategic Initiatives
7.4.9. Merck KGaA
7.4.9.1. Participant’s Overview
7.4.9.2. Financial Performance
7.4.9.3. Product Benchmarking
7.4.9.4. Recent Developments/ Strategic Initiatives
7.4.10. Sanofi
7.4.10.1. Participant’s Overview
7.4.10.2. Financial Performance
7.4.10.3. Product Benchmarking
7.4.10.4. Recent Developments/ Strategic Initiatives
7.4.11. Alnylam Pharmaceuticals, Inc.
7.4.11.1. Participant’s Overview
7.4.11.2. Financial Performance
7.4.11.3. Product Benchmarking
7.4.11.4. Recent Developments/ Strategic Initiatives